Brainomix, a U.K.-based medical imaging company focused on artificial intelligence (AI), announced Tuesday, April 3, that it has secured $9.8 million (£7 million) to help market its software for treating stroke victims throughout the world. e-ASPECTS, which Brainomix markets as its flagship software solution, uses AI to provide “fast and standardized assessment of stroke patient CT scans.” It was developed to improve stroke treatment at a lower cost. “Since we started as a spin-out of the University of Oxford we have become a global market leader, with our stroke decision support and workflow tools installed in many leading stroke centres in more than 16 countries,” Michalis Papadakis, Brainomix CEO, said in a prepared statement. “With this investment we will grow around the world and continuously expand Brainomix’s intelligent imaging software for acute stroke care and clinical trials.” FDA approval for e-ASPECTS is pending.
University of Oxford spin - out Brainomix has secured £ 7 m ( $ 9.8 m ) to market its artificial intelligence ( AI ) e - Aspects software . The company said the system offers a " fast and standardised collection of stroke patient CT scans " , and helps reduce the cost of surgery . Brainomix 's CEO , Michalis Papadakis , said the company will focus on expanding both its software and global footprint . The company is seeking approval for the software from the uk 's Food and Drug Administration .